Madison, WI, USA and Malmö, SE. Apr. 16, 2020 — Nimble Therapeutics and Svar Life Science today announced a collaboration to discover, develop, and commercialize diagnostic tests based on Nimble’s powerful and broadly applicable biomarker discovery engine and Svar’s strong in vitro diagnostic test development and commercialization expertise.
The collaboration initially will leverage a novel panel of rheumatoid arthritis biomarkers discovered using Nimble’s comprehensive human proteome immunoprofiling.
“We are excited to partner with a leading, well-respected life science company like Svar. Their reputation for high-quality tests and strong global presence makes them an ideal partner for Nimble.” said Jigar Patel, Ph.D., Chief Executive Officer of Nimble Therapeutics. “This collaboration combines the strengths of our two organizations to potentially bring new and improved tests to patients with autoimmune disorders.”
Bradley Garcia, Nimble’s VP of Corporate Development notes, “This collaboration is validation of Nimble’s powerful discovery platform and partnering with Svar provides a strong commercial outlet for Nimble’s discovery capabilities”.
Svar Life Science has a strong track record in pioneering new solutions within clinical diagnostics and drug discovery. For over 30 years, Svar has been working across the clinical diagnostic value chain, with a special focus on autoimmunity, IBD and rheumatoid arthritis.
“We are delighted to partner with an innovative and entrepreneurial company like Nimble Therapeutics. Their powerful, cutting edge biomarker discovery platform in combination with our experience and expertise creates a strong foundation and supports our strategy to bring forward novel solutions to improve clinical outcome of patients” says Jörgen Dahlström, Ph.D., Chief Executive Officer of Svar Life Science.
“This agreement exemplifies how we collaborate with innovative companies to discover, develop and commercialize solutions which support drug development and enable clinical diagnosis” notes Frida Pauly, Director Business Development at Svar.
Under the terms of the agreement, Nimble will receive an undisclosed upfront payment and will be eligible for downstream milestone payments and royalties on product sales.
